Katherine Poinsatte, PhD, Science Writer —

A Phase 1 trial that’s evaluating the safety and tolerability of an inhaled treatment called KIT2014 in healthy volunteers has started in Australia. KIT2014 is being developed by Kither Biotech as an add-on to existing CTFR modulators, to improve lung function and reduce inflammation in cystic fibrosis (CF)…

A new Cystic Fibrosis Innovation Hub has been launched in the U.K. to accelerate the development of new tests and treatments for lung infections in cystic fibrosis (CF) patients. This University of Liverpool-based hub will join a Translational Innovation Hub Network, which includes hubs led by the University of…

The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to ETD001, an investigational therapy aiming to improve mucus clearance in people with cystic fibrosis (CF). The designation is awarded by the FDA to aid the development of treatments for serious or life-threatening rare diseases —…

Non-white Canadians with cystic fibrosis (CF) have a higher risk of death than white Canadians with the disease, according to a study of nearly 6,000 people with CF. Despite having similar characteristics at diagnosis and similar rates of CF complications, non-white CF patients also had worse lung function,…